Santhera poaches Vifor CCO as it looks to become leader in DMD

Switzerland’s Santhera Pharmaceuticals has poached Vifor Pharma’s Chief Commercial Officer, Dario Eklund, to serve as its new CEO.

Thomas Meier will remain in his role as CEO until December 1 at which time he will step down. He will continue as a board member and will chair the board’s newly formed Scientific Committee.

To ensure a smooth leadership transition, he will also serve as a special advisor to Mr Eklund.

Prior to his role with Vifor Pharma, Mr Eklund spent a decade in Boston as Vice President and a member of the Executive Committee at Organogenesis, a Nasdaq-listed specialist in regenerative medicine and cell therapy with three approved products.

Puldysa (idebenone) is currently under review by the European Medicines Agency as treatment for patients with Duchenne muscular dystrophy (DMD) and vamorolone, a first-in-class steroidal drug, is in a pivotal DMD trial.

Vifor said that it expects market entries for both products next year as it gears up for commercial preparations both in the US and Europe.

“As we transition to become a leader in innovative treatments for rare neuromuscular and pulmonary diseases it is important for Santhera to be led by a CEO with international commercial experience,” said Mr Meier.

“Dario shares my belief in Santhera’s potential and excitement about the future opportunities for the Company and he will contribute the perfect blend of global commercial expertise and management skills to lead Santhera into the growth phase ahead.”

Mr Eklund added: “With two late-stage DMD drug candidates covering essentially the entire disease spectrum in all patients, Santhera is poised to become the world leader in an area where the unmet medical need is significant.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Related news

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...